As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

The former CEO of the collagen company is now leading Supergut, which plays in an emerging but competitive category of ...

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Compounded Ozempic and Wegovy, cheaper generic versions of the weight-loss drugs, can no longer be sold. Doctor explains ...

Behind the scenes, it ran real-time social listening to track sentiment and found discussions around GLP-1s rose 50% during ...

In the December quarter, the company's management said it plans to double the firm's pen capacity over the next couple of ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

Jamie Mafdali of South Florida was hit with a cancer double-whammy three years ago. Shortly after her mother began treatment ...